CY1112615T1 - Ταχεως διασπωμενο δισκιο το οποιο περιεχει ενα ασταθες σε οξυ δραστικο συστατικο - Google Patents

Ταχεως διασπωμενο δισκιο το οποιο περιεχει ενα ασταθες σε οξυ δραστικο συστατικο

Info

Publication number
CY1112615T1
CY1112615T1 CY20121100345T CY121100345T CY1112615T1 CY 1112615 T1 CY1112615 T1 CY 1112615T1 CY 20121100345 T CY20121100345 T CY 20121100345T CY 121100345 T CY121100345 T CY 121100345T CY 1112615 T1 CY1112615 T1 CY 1112615T1
Authority
CY
Cyprus
Prior art keywords
active ingredient
tablet
instability
oral administration
acid active
Prior art date
Application number
CY20121100345T
Other languages
Greek (el)
English (en)
Inventor
Rango Dietrich
Rudolf Linder
Hartmut Ney
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of CY1112615T1 publication Critical patent/CY1112615T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
CY20121100345T 2000-12-07 2012-04-09 Ταχεως διασπωμενο δισκιο το οποιο περιεχει ενα ασταθες σε οξυ δραστικο συστατικο CY1112615T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126807 2000-12-07
EP01999360A EP1341528B1 (en) 2000-12-07 2001-12-06 Rapidly disintegrating tablet comprising an acid-labile active ingredient

Publications (1)

Publication Number Publication Date
CY1112615T1 true CY1112615T1 (el) 2016-02-10

Family

ID=8170591

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100345T CY1112615T1 (el) 2000-12-07 2012-04-09 Ταχεως διασπωμενο δισκιο το οποιο περιεχει ενα ασταθες σε οξυ δραστικο συστατικο

Country Status (15)

Country Link
US (1) US7147869B2 (https=)
EP (1) EP1341528B1 (https=)
JP (1) JP2004514737A (https=)
KR (1) KR20030072555A (https=)
CN (1) CN100335040C (https=)
AT (1) ATE541564T1 (https=)
AU (1) AU2002221939A1 (https=)
BR (1) BR0115986A (https=)
CA (1) CA2430829C (https=)
CY (1) CY1112615T1 (https=)
DK (1) DK1341528T3 (https=)
ES (1) ES2380654T3 (https=)
PT (1) PT1341528E (https=)
SI (1) SI1341528T1 (https=)
WO (1) WO2002045694A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
EP1341524B1 (en) * 2000-12-07 2011-10-19 Nycomed GmbH Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
CA2430824C (en) * 2000-12-07 2012-05-08 Altana Pharma Ag Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
AU2002316020B2 (en) * 2001-07-16 2007-03-15 Astrazeneca Ab Pharmaceutical formulation comprising a proton pump inhibitor and antacids
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
ES2335498T3 (es) 2003-03-10 2010-03-29 Nycomed Gmbh Nuevo proceso para la preparacion de reflumilast.
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
US8461187B2 (en) * 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8758814B2 (en) * 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
US8057820B2 (en) * 2004-10-08 2011-11-15 Mcneil-Ppc, Inc. Enteric coated aspirin granules comingled with binder
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
CN100431526C (zh) * 2005-11-07 2008-11-12 上海艾力斯医药科技有限公司 一种酸敏感型药物的快速崩解片剂
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8425935B2 (en) * 2005-12-21 2013-04-23 Basf Se Pharmaceutical formulation for producing rapidly disintegrating tablets
MX2009013063A (es) * 2007-06-06 2010-01-15 Basf Se Formulacion farmaceutica para la produccion de tabletas de desintegracion rapida.
EP2164460B1 (de) * 2007-06-06 2017-08-09 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
WO2009049160A1 (en) * 2007-10-12 2009-04-16 Takeda Pharmaceuticals North America Methods of treating gastrointestinal disorders independent of the intake of food
DE102010011421A1 (de) * 2009-03-19 2010-09-30 Schaeffler Technologies Gmbh & Co. Kg Schaltbarer Schlepphebel eines Ventiltriebs einer Brennkraftmaschine
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2011112771A1 (en) * 2010-03-11 2011-09-15 Rich Vitamins Llc Quick dissolve nutritional powder
EP2441446A1 (en) * 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi Using of superdisintegrants in cetyl myristate and/or cetyl palmitate formulations
EP2589378A1 (en) * 2010-10-14 2013-05-08 Deva Holding Anonim Sirketi Coating of cetyl myristate and/or cetyl palmitate particles
US8709310B2 (en) 2011-01-05 2014-04-29 Hospira, Inc. Spray drying vancomycin
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN120585773B (zh) * 2025-08-06 2025-11-07 广州仁恒医药科技股份有限公司 一种盐酸米诺环素胶囊及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065142A (en) 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US4006227A (en) * 1973-11-15 1977-02-01 Gallegos Alfred J Compositions and methods for fertility control
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
JP2948317B2 (ja) 1991-05-28 1999-09-13 マクニール―ピーピーシー・インコーポレーテツド 噛める薬物投与用組成物
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
ATE253899T1 (de) * 1994-01-31 2003-11-15 Yamanouchi Pharma Co Ltd Intraoral löslicher formpressling und verfahren zu seiner herstellung
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
DK0723436T3 (da) 1994-07-08 2001-11-26 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
JP4939680B2 (ja) * 1997-05-27 2012-05-30 武田薬品工業株式会社 固形製剤
CA2315088A1 (en) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
DE69934505T2 (de) * 1998-05-18 2007-10-04 Takeda Pharmaceutical Co. Ltd. Im munde zerfallende tablette enthaltend ein benzimidazole
TW585786B (en) * 1998-07-28 2004-05-01 Takeda Chemical Industries Ltd Lansoprazole-containing rapidly disintegrable solid pharmaceutical composition
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
DE19925710C2 (de) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
ES2246238T3 (es) 1999-06-07 2006-02-16 Altana Pharma Ag Nueva preparacion y forma de administracion que comprende un inhibidor de las bombas de protones labil en medio acido.

Also Published As

Publication number Publication date
WO2002045694A1 (en) 2002-06-13
EP1341528A1 (en) 2003-09-10
BR0115986A (pt) 2003-12-23
CN100335040C (zh) 2007-09-05
AU2002221939A1 (en) 2002-06-18
US7147869B2 (en) 2006-12-12
CA2430829C (en) 2010-06-22
KR20030072555A (ko) 2003-09-15
HK1062264A1 (zh) 2004-10-29
ES2380654T3 (es) 2012-05-17
US20040110661A1 (en) 2004-06-10
JP2004514737A (ja) 2004-05-20
SI1341528T1 (sl) 2012-05-31
PT1341528E (pt) 2012-03-20
DK1341528T3 (da) 2012-03-26
ATE541564T1 (de) 2012-02-15
EP1341528B1 (en) 2012-01-18
CA2430829A1 (en) 2002-06-13
CN1479613A (zh) 2004-03-03

Similar Documents

Publication Publication Date Title
CY1112615T1 (el) Ταχεως διασπωμενο δισκιο το οποιο περιεχει ενα ασταθες σε οξυ δραστικο συστατικο
CY1112333T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει μια δραστικη ουσια πανω σε μια μητρα
HUP0201637A2 (hu) Savval szemben labilis vegyületet tartalmazó új készítmény és adagolási forma
BR9611802A (pt) Composições farmacêuticas
GR890100467A (el) Μεθοδος δια την παρασκευη ενδοφλεβιου φαρμακευτικης συνθεσεως.
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
ES2158908T3 (es) Formulaciones en aerosol sin clorofluorocarbonos.
IT1219750B (it) Forma di dosaggio per rilascio con tinuato di sostanze farmaceutiche e simili
DE50104138D1 (de) Injizierbare pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend mittelkettige triglyceride
MXPA02003321A (es) Composiciones de liberacion controlada que comprenden nimesulida.
ATE226815T1 (de) Herstellung von arzneimitteln
SE9704401D0 (sv) Matrix pellets for greasy, oily or sticky drug substances
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
CO4910117A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
YU17899A (sh) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
ES2178653T3 (es) Nuevos preparados farmaceuticos para la administracion oral que contienen ciclosporina.
SE9704400D0 (sv) Porous inorganic particles as carriers for drug substances
ES2156220T3 (es) Preparacion transdermica que contiene un metabolito de loratidina con accion antihistaminica.
ES2103369T3 (es) Derivados de lanolina como sustancias que aceleran la penetracion y su aplicacion en sustancias farmaceuticas u otras formulaciones que contienen sustancias biologicamente activas.
AR002972A1 (es) Pildoras que tienen una matriz farmaceutica que proporcionan un perfil apropiado de liberacion de la droga, composicion para la preparacion de dichamatriz, proceso para preparar dichas pildoras y formas de dosificacion de dicha composicion.
HUP9700842A1 (hu) Hatóanyagok szabályozott felszabadulását biztosító, stabilizált lipofil mátrixalapú gyógyászati készítmények
DE69712055D1 (de) Pharmazeutische zusammensetzungen enthaltend cyclosporin und einen träger mit mindestens einer ester-alpha-glycerophosphorsäure
NO996074D0 (no) Voksestere anriket i <omega>-3 umettede fettsyrer, deres fremstilling og deres anvendelse